$GRCE

2022 Q1 Form 10-Q Financial Statement

#000095017022001147 Filed on February 14, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q4 2021 Q3
Revenue $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Cost Of Revenue $0.00 $0.00
YoY Change -100.0% -100.0%
Gross Profit $0.00 $0.00
YoY Change -100.0% -100.0%
Gross Profit Margin
Selling, General & Admin $2.077M $2.046M $2.982M
YoY Change 37.64% 53.72% 104.53%
% of Gross Profit
Research & Development $848.0K $2.179M $585.0K
YoY Change 115.78% 221.39% -54.51%
% of Gross Profit
Depreciation & Amortization $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
% of Gross Profit
Operating Expenses $4.403M $4.225M $3.567M
YoY Change 124.41% 110.3% 29.99%
Operating Profit -$4.403M -$4.474M -$3.567M
YoY Change 133.33% 127.8% -55.6%
Interest Expense -$296.0K $696.0K $4.548M
YoY Change -91.15% -155.41% 124.04%
% of Operating Profit
Other Income/Expense, Net $147.0K $696.0K $4.548M
YoY Change -155.41% 140.89%
Pretax Income -$4.552M -$3.778M $981.0K
YoY Change -19.38% 17.33% -115.96%
Income Tax -$648.0K $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings -$3.904M -$3.778M $981.0K
YoY Change -30.85% 17.33% -115.96%
Net Earnings / Revenue
Basic Earnings Per Share -$0.09 -$0.03
Diluted Earnings Per Share -$106.0K -$85.30K $29.92K
COMMON SHARES
Basic Shares Outstanding 44.29M 44.29M 208.4M
Diluted Shares Outstanding 44.29M 32.79M

Balance Sheet

Concept 2022 Q1 2021 Q4 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $43.66M $46.33M $50.79M
YoY Change -28.11% 65.93% 339.66%
Cash & Equivalents $30.34M $33.01M $36.93M
Short-Term Investments $13.32M $13.31M $13.86M
Other Short-Term Assets $1.322M $2.434M $2.942M
YoY Change 18.99% 47.78% 91.54%
Inventory
Prepaid Expenses $720.0K $1.847M $2.178M
Receivables $548.0K $238.0K $813.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $45.28M $49.00M $54.55M
YoY Change -27.4% 62.25% 297.76%
LONG-TERM ASSETS
Property, Plant & Equipment $20.89M $22.00K $43.00K
YoY Change -79.05% -63.87%
Goodwill $12.96M
YoY Change
Intangibles $69.81M $65.21M $65.21M
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $83.34M $65.23M $65.25M
YoY Change 96805.81% 62023.81% 54732.77%
TOTAL ASSETS
Total Short-Term Assets $45.28M $49.00M $54.55M
Total Long-Term Assets $83.34M $65.23M $65.25M
Total Assets $128.6M $114.2M $119.8M
YoY Change 105.93% 276.95% 766.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.156M $2.843M $4.433M
YoY Change 2644.35% 35.38% 20.79%
Accrued Expenses $296.0K $22.00K $43.00K
YoY Change -51.24% -79.05% -46.91%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.260M $2.897M $4.476M
YoY Change 106.46% 28.87% 19.33%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $201.0K $268.0K $1.116M
YoY Change -96.15% -88.55% -7.62%
Total Long-Term Liabilities $201.0K $268.0K $1.116M
YoY Change -96.15% -88.55% -7.62%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.260M $2.897M $4.476M
Total Long-Term Liabilities $201.0K $268.0K $1.116M
Total Liabilities $20.35M $3.165M $5.592M
YoY Change 199.35% -31.02% 12.76%
SHAREHOLDERS EQUITY
Retained Earnings -$155.8M -$151.9M -$148.2M
YoY Change 6.72% 8.24% 8.02%
Common Stock $258.0M $258.0M $258.0M
YoY Change 30.83% 59.06% 80.96%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $108.3M $111.1M $114.2M
YoY Change
Total Liabilities & Shareholders Equity $128.6M $114.2M $119.8M
YoY Change 105.93% 276.95% 766.08%

Cashflow Statement

Concept 2022 Q1 2021 Q4 2021 Q3
OPERATING ACTIVITIES
Net Income -$3.904M -$3.778M $981.0K
YoY Change -30.85% 17.33% -115.96%
Depreciation, Depletion And Amortization $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Operating Activities -$3.145M -$4.584M -$6.104M
YoY Change 78.69% 8.78% 46.1%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $11.00K $557.0K $2.837M
YoY Change -100.13% -140.6%
Cash From Investing Activities $11.00K $557.0K $2.837M
YoY Change -100.13% -140.6% -8696.97%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00 $0.00
YoY Change -100.0% -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 $0.00
YoY Change -100.0% -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -3.145M -4.584M -$6.104M
Cash From Investing Activities 11.00K 557.0K $2.837M
Cash From Financing Activities 0.000 0.000 $0.00
Net Change In Cash -3.134M -3.916M -$4.046M
YoY Change -112.79% -126.12% 609.82%
FREE CASH FLOW
Cash From Operating Activities -$3.145M -$4.584M -$6.104M
Capital Expenditures $0.00 $0.00 $0.00
Free Cash Flow -$3.145M -$4.584M -$6.104M
YoY Change 78.69% 8.78% 47.26%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q4 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
dei Entity Central Index Key
EntityCentralIndexKey
0001444192
dei Amendment Flag
AmendmentFlag
false
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--03-31
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35776
dei Entity Registrant Name
EntityRegistrantName
Acasti Pharma Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
Z4
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1359336
dei Entity Address Address Line1
EntityAddressAddressLine1
3009 boul. de la Concorde East, Suite 102
dei Entity Address City Or Town
EntityAddressCityOrTown
Laval
dei Entity Address State Or Province
EntityAddressStateOrProvince
QC
dei Entity Address Country
EntityAddressCountry
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
H7E 2B5
dei City Area Code
CityAreaCode
450
dei Local Phone Number
LocalPhoneNumber
686-4555
dei Security12b Title
Security12bTitle
Common Shares, no par value per share
dei Trading Symbol
TradingSymbol
ACST
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
44288183
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
33013000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50942000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
13312000
CY2021Q1 us-gaap Short Term Investments
ShortTermInvestments
9789000
CY2021Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
238000
CY2021Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
530000
CY2021Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
587000
CY2021Q1 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
768000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1847000
CY2021Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
343000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
48997000
CY2021Q1 us-gaap Assets Current
AssetsCurrent
62372000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
22000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
86000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
65208000
CY2021Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
0
CY2021Q4 us-gaap Assets
Assets
114227000
CY2021Q1 us-gaap Assets
Assets
62458000
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2843000
CY2021Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1493000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
22000
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
86000
CY2021Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
32000
CY2021Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2897000
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1579000
CY2021Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
268000
CY2021Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
5219000
CY2021Q4 us-gaap Liabilities
Liabilities
3165000
CY2021Q1 us-gaap Liabilities
Liabilities
6798000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
257990000
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
197194000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
11538000
CY2021Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
10817000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6533000
CY2021Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6333000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-151933000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
20000
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-146018000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
111062000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
55660000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
114227000
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
62458000
CY2021Q4 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
CY2020Q4 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
81000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
81000
CY2021Q4 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0
CY2020Q4 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
36000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
36000
CY2021Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2179000
CY2020Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
678000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3233000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3720000
CY2021Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1808000
CY2020Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1105000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7441000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4078000
CY2021Q4 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
238000
CY2020Q4 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
226000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
263000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1076000
CY2021Q4 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2020Q4 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
3706000
CY2021Q4 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2020Q4 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
1584000
CY2021Q4 acst Impairment Of Other Assets And Prepaids
ImpairmentOfOtherAssetsAndPrepaids
-249000
CY2020Q4 acst Impairment Of Other Assets And Prepaids
ImpairmentOfOtherAssetsAndPrepaids
0
acst Impairment Of Other Assets And Prepaids
ImpairmentOfOtherAssetsAndPrepaids
-249000
acst Impairment Of Other Assets And Prepaids
ImpairmentOfOtherAssetsAndPrepaids
0
CY2021Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-4474000
CY2020Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-1964000
us-gaap Operating Income Loss
OperatingIncomeLoss
-11186000
us-gaap Operating Income Loss
OperatingIncomeLoss
-14119000
CY2021Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
696000
CY2020Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1256000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5271000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
87000
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-3778000
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
-3220000
us-gaap Net Income Loss
NetIncomeLoss
-5915000
us-gaap Net Income Loss
NetIncomeLoss
-14032000
CY2021Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
CY2020Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.26
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.23
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.18
CY2021Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
44288183
CY2020Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12533584
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
25785579
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11922119
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
55660000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-3118000
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
762000
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
153000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
53457000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
981000
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1149000
CY2021Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
114000
CY2021Q3 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
60801000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
114204000
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-3778000
CY2021Q4 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
187000
CY2021Q4 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
454000
CY2021Q4 us-gaap Exchange Fees
ExchangeFees
5000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
111062000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
12994000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-4666000
CY2020Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
308000
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1765000
CY2020Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
635000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
11036000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-6146000
CY2020Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
179000
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3427000
CY2020Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
377000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
8873000
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
-3220000
CY2020Q4 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
466000
CY2020Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
19626000
CY2020Q4 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-30000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
25715000
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-3778000
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
-3220000
us-gaap Net Income Loss
NetIncomeLoss
-5915000
us-gaap Net Income Loss
NetIncomeLoss
-14032000
CY2021Q4 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2020Q4 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
781000
CY2021Q4 us-gaap Depreciation
Depreciation
0
CY2020Q4 us-gaap Depreciation
Depreciation
0
us-gaap Depreciation
Depreciation
0
us-gaap Depreciation
Depreciation
142000
CY2021Q4 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2020Q4 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
3706000
CY2021Q4 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2020Q4 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
1584000
CY2021Q4 acst Impairment Of Other Assets And Prepaids
ImpairmentOfOtherAssetsAndPrepaids
-249000
CY2020Q4 acst Impairment Of Other Assets And Prepaids
ImpairmentOfOtherAssetsAndPrepaids
-0
acst Impairment Of Other Assets And Prepaids
ImpairmentOfOtherAssetsAndPrepaids
-249000
acst Impairment Of Other Assets And Prepaids
ImpairmentOfOtherAssetsAndPrepaids
-0
CY2021Q4 us-gaap Share Based Compensation
ShareBasedCompensation
454000
CY2020Q4 us-gaap Share Based Compensation
ShareBasedCompensation
-30000
us-gaap Share Based Compensation
ShareBasedCompensation
721000
us-gaap Share Based Compensation
ShareBasedCompensation
1003000
CY2021Q4 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-828000
CY2020Q4 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1098000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-4908000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-420000
CY2021Q4 acst Write Off Of Deferred Financing Costs Of At The Market Program
WriteOffOfDeferredFinancingCostsOfAtTheMarketProgram
0
CY2020Q4 acst Write Off Of Deferred Financing Costs Of At The Market Program
WriteOffOfDeferredFinancingCostsOfAtTheMarketProgram
0
acst Write Off Of Deferred Financing Costs Of At The Market Program
WriteOffOfDeferredFinancingCostsOfAtTheMarketProgram
0
acst Write Off Of Deferred Financing Costs Of At The Market Program
WriteOffOfDeferredFinancingCostsOfAtTheMarketProgram
264000
CY2021Q4 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-2000
CY2020Q4 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
54000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
418000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
208000
CY2021Q4 acst Increase Decrease In Working Capital
IncreaseDecreaseInWorkingCapital
683000
CY2020Q4 acst Increase Decrease In Working Capital
IncreaseDecreaseInWorkingCapital
2008000
acst Increase Decrease In Working Capital
IncreaseDecreaseInWorkingCapital
3818000
acst Increase Decrease In Working Capital
IncreaseDecreaseInWorkingCapital
5379000
CY2021Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4584000
CY2020Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4214000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14089000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12559000
CY2021Q4 us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
0
CY2020Q4 us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
0
us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
0
us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
69000
CY2021Q4 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
13324000
CY2020Q4 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
1372000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
34852000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
1393000
CY2021Q4 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
13881000
CY2020Q4 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
0
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
31319000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
21000
CY2021Q4 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
557000
CY2020Q4 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1372000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3533000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1441000
CY2021Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2020Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
19745000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
24955000
CY2021Q4 acst Payments For Proceeds From Financing Costs
PaymentsForProceedsFromFinancingCosts
0
CY2020Q4 acst Payments For Proceeds From Financing Costs
PaymentsForProceedsFromFinancingCosts
0
acst Payments For Proceeds From Financing Costs
PaymentsForProceedsFromFinancingCosts
0
acst Payments For Proceeds From Financing Costs
PaymentsForProceedsFromFinancingCosts
143000
CY2021Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
CY2020Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19745000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
24812000
CY2021Q4 acst Effect Of Translation Effect On Cash And Cash Equivalents
EffectOfTranslationEffectOnCashAndCashEquivalents
136000
CY2020Q4 acst Effect Of Translation Effect On Cash And Cash Equivalents
EffectOfTranslationEffectOnCashAndCashEquivalents
-1843000
acst Effect Of Translation Effect On Cash And Cash Equivalents
EffectOfTranslationEffectOnCashAndCashEquivalents
-176000
acst Effect Of Translation Effect On Cash And Cash Equivalents
EffectOfTranslationEffectOnCashAndCashEquivalents
-1993000
CY2021Q4 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-25000
CY2020Q4 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2678000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-131000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3487000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3916000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
14994000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-17929000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
12306000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
36929000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11552000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
50942000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14240000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
33013000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
26546000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
33013000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
26546000
CY2021Q4 us-gaap Cash
Cash
33013000
CY2020Q4 us-gaap Cash
Cash
7104000
CY2021Q4 us-gaap Cash
Cash
33013000
CY2020Q4 us-gaap Cash
Cash
7104000
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2020Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
19442000
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2020Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
19442000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1507000
us-gaap Nature Of Operations
NatureOfOperations
<p style="margin-left:1.2%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;">1. Nature of operation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"> </span> </p><p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Acasti Pharma Inc. (“Acasti” or the “Corporation”) is incorporated under the Business Corporations Act (Québec) (formerly Part 1A of the Companies Act (Québec)). The Corporation is domiciled in Canada and its registered office is located at 3009 boul. de la Concorde East, Suite 102, Laval, Québec, Canada H7E 2B5.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"> </span> </p><p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">In January 2020 and August 2020, the Corporation released Phase 3 TRILOGY clinical study results for the Corporation’s lead drug candidate, CaPre. The TRILOGY studies did not meet the primary endpoint which resulted in the Corporation’s Board of Directors deciding not to proceed with a filing of an NDA with the FDA. With the completion of the TRILOGY studies beginning in the second half of fiscal 2021, marketing and research and development activities and expenses were reduced while management undertook a strategic review, and some CaPre related equipment and other assets were and continue to be classified as held for sale as they are expected to be sold.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"> </span> </p><p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">In August 2021, the Corporation completed the acquisition via a share-for-share merger of Grace Therapeutics, Inc. (“Grace”) a privately held emerging biopharmaceutical company focused on developing innovative drug delivery technologies for the treatment of rare and orphan diseases. The post-merger Corporation is focused on building a late-stage specialty pharmaceutical company specializing in rare and orphan diseases and focused on developing and commercializing products that improve clinical outcomes using novel drug delivery technologies. The Corporation seeks to apply new proprietary formulations to existing pharmaceutical compounds to achieve enhanced efficacy, faster onset of action, reduced side effects, more convenient delivery and increased patient compliance; all of which could result in improved patient outcomes. The active pharmaceutical ingredients chosen by the Corporation for further development may be already approved in the target indication or could be repurposed for use in new indications.</span></p><p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"> </span> </p><p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">The Corporation has incurred operating losses and negative cash flows from operations in each year since its inception. The Corporation expects to incur significant expenses and continued operating losses for the foreseeable future. The Corporation expects its expenses will increase substantially in connection with its ongoing activities, particularly as it advances clinical development for the first three drug candidates in the Corporation’s pipeline; continues to engage contract manufacturing organizations (“CMOs”) to manufacture its clinical study materials and to ultimately develop large-scale manufacturing capabilities in preparation for commercial launch; seeks regulatory approval for its product candidates; and adds personnel to support its product development and future product launch and commercialization.</span></p><p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"> </span> </p><p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">The Corporation does not expect to generate revenue from product sales unless and until it successfully completes drug development and obtains regulatory approval, which the Corporation expects will take several years and is subject to significant uncertainty. To date, the Corporation has financed its operations primarily through public offerings and private placements of its common shares, warrants and convertible debt and the proceeds from research tax credits. Until such time that the Corporation can generate significant revenue from product sales, if ever, it will require additional financing, which is expected to be sourced from a combination of public or private equity or debt financings or other non-dilutive sources, which may include fees, milestone payments and royalties from collaborations with third parties. Arrangements with collaborators or others may require the Corporation to relinquish certain rights related to its technologies or drug product candidates. Adequate additional financing may not be available to the Corporation on acceptable terms, or at all. The Corporation’s inability to raise capital as and when needed would have a negative impact on its financial condition and its ability to pursue its business strategy.</span></p><p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"> </span> </p><p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">The Corporation remains subject to risks similar to other development stage companies in the biopharmaceutical industry, including compliance with government regulations, protection of proprietary technology, dependence on third party contractors and consultants and potential product liability, among others.</span></p><p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"> </span> </p><p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;font-style:italic;">Reverse stock split</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"> </span> </p><p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">On August 26, 2021, the shareholders of the Corporation approved a resolution to undertake a reverse split of the common stock within a range of 1-6 to 1-8 with such specific ratio to be approved by the Acasti Board. All references in these financial statements to number of common shares, warrants and options, price per share and weighted average number of shares outstanding prior to the reverse split have been adjusted to reflect the approved reverse stock split of 1-</span><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">, which was made effective on August 31, 2021, on a retroactive basis as of the earliest period presented.</span></p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;font-style:italic;">Use of estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"> </span> </p><p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">The preparation of these financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, income, and expenses. Actual results may differ from these estimates.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"> </span> </p><p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Estimates are based on management’s best knowledge of current events and actions that management may undertake in the future. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</span></p><p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"> </span> </p><p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Estimates and assumptions include the measurement of derivative warrant liabilities (note 8), stock-based compensation (note 12), assets held for sale (note 5), supply agreement (note 15), acquisition of Grace and valuation of intangibles (note 4). Estimates and assumptions are also involved in measuring the accrual of services rendered with respect to research and development expenditures at each reporting date, including whether contingencies should be accrued for, as well as in determining which research and development expenses qualify for investment tax credits and in what amounts. The Corporation recognizes the tax credits once it has reasonable assurance that they will be realized. Recorded tax credits are subject to review and approval by tax authorities and, therefore, could be different from the amounts recorded.</span></p><p style="margin-left:1.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"> </span> </p>
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0147
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0
CY2020Q4 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
14000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
14000
CY2021Q4 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-331000
CY2020Q4 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
23000
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-9670000
CY2021Q4 us-gaap Marketable Securities
MarketableSecurities
13312000
CY2021Q1 us-gaap Marketable Securities
MarketableSecurities
9789000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0147
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M7D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M7D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020Q3 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
3706000
CY2021Q4 acst Impairment Of Other Assets And Prepaids
ImpairmentOfOtherAssetsAndPrepaids
-249000
acst Impairment Of Other Assets And Prepaids
ImpairmentOfOtherAssetsAndPrepaids
-249000
CY2019Q1 acst Atthemarket Sales Agreement Common Stock Maximum Amount
AtthemarketSalesAgreementCommonStockMaximumAmount
30000000
CY2019Q1 acst Atthemarket Sales Agreement Term
AtthemarketSalesAgreementTerm
P3Y
CY2020Q2 acst Atthemarket Sales Agreement Common Stock Maximum Amount
AtthemarketSalesAgreementCommonStockMaximumAmount
75000000
CY2020Q2 acst Atthemarket Sales Agreement Underwriter Fees Percentage Of Sales
AtthemarketSalesAgreementUnderwriterFeesPercentageOfSales
0.030
CY2019Q1 acst Write Off Of Deferred Financing Costs Of At The Market Program
WriteOffOfDeferredFinancingCostsOfAtTheMarketProgram
115000
CY2021Q4 acst Atthemarket Sales Agreement Common Stock Maximum Amount
AtthemarketSalesAgreementCommonStockMaximumAmount
75000000
acst Write Off Of Deferred Financing Costs Of At The Market Program
WriteOffOfDeferredFinancingCostsOfAtTheMarketProgram
264000
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
247881
CY2021Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
792000
CY2021Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
247881
CY2021Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
792000
acst Proceeds From Nrcirap
ProceedsFromNRCIRAP
0
acst Proceeds From Nrcirap
ProceedsFromNRCIRAP
79000
CY2021Q4 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-579000
CY2020Q4 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-27000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-292000
CY2021Q4 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-172000
CY2020Q4 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-196000
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
172000
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-146000
acst Write Off Of Deferred Financing Costs Of At The Market Program
WriteOffOfDeferredFinancingCostsOfAtTheMarketProgram
0
acst Write Off Of Deferred Financing Costs Of At The Market Program
WriteOffOfDeferredFinancingCostsOfAtTheMarketProgram
264000
CY2021Q4 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-828000
CY2020Q4 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1098000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-4908000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-420000
CY2021Q4 us-gaap Investment Income Interest
InvestmentIncomeInterest
40000
CY2020Q4 us-gaap Investment Income Interest
InvestmentIncomeInterest
38000
us-gaap Investment Income Interest
InvestmentIncomeInterest
191000
us-gaap Investment Income Interest
InvestmentIncomeInterest
77000
CY2021Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
696000
CY2020Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1256000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5271000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
87000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
2.05
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
0
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
2.05
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
0
CY2021Q4 us-gaap Share Price
SharePrice
2.05
CY2020Q4 us-gaap Share Price
SharePrice
0
CY2021Q4 us-gaap Share Price
SharePrice
2.05
CY2020Q4 us-gaap Share Price
SharePrice
0
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
1.76
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
0
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
1.76
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
0
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.2066
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.2066
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-521000
CY2021Q4 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1593000
CY2020Q4 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1999000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2603000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-5891000
CY2021Q4 acst Increase Decrease In Non Cash Working Capital
IncreaseDecreaseInNonCashWorkingCapital
683000
CY2020Q4 acst Increase Decrease In Non Cash Working Capital
IncreaseDecreaseInNonCashWorkingCapital
2009000
acst Increase Decrease In Non Cash Working Capital
IncreaseDecreaseInNonCashWorkingCapital
3818000
acst Increase Decrease In Non Cash Working Capital
IncreaseDecreaseInNonCashWorkingCapital
5404000

Files In Submission

Name View Source Status
0000950170-22-001147-index-headers.html Edgar Link pending
0000950170-22-001147-index.html Edgar Link pending
0000950170-22-001147.txt Edgar Link pending
0000950170-22-001147-xbrl.zip Edgar Link pending
acst-20211231.htm Edgar Link pending
acst-20211231.xsd Edgar Link pending
acst-ex31_1.htm Edgar Link pending
acst-ex31_2.htm Edgar Link pending
acst-ex32_1.htm Edgar Link pending
acst-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img178598726_0.jpg Edgar Link pending
img178598726_1.jpg Edgar Link pending
img178598726_10.jpg Edgar Link pending
img178598726_2.jpg Edgar Link pending
img178598726_3.jpg Edgar Link pending
img178598726_4.jpg Edgar Link pending
img178598726_5.jpg Edgar Link pending
img178598726_6.jpg Edgar Link pending
img178598726_7.jpg Edgar Link pending
img178598726_8.jpg Edgar Link pending
img178598726_9.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
acst-20211231_cal.xml Edgar Link unprocessable
acst-20211231_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
acst-20211231_pre.xml Edgar Link unprocessable
acst-20211231_def.xml Edgar Link unprocessable
acst-20211231_htm.xml Edgar Link completed
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending